Altimmune
ALT
88 hedge funds and large institutions have $231M invested in Altimmune in 2020 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 27 increasing their positions, 16 reducing their positions, and 21 closing their positions.
76% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 21
69% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 16
22% more funds holding
Funds holding: 72 → 88 (+16)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4.73% less ownership
Funds ownership: 66.54% → 61.81% (-4.7%)
19% less capital invested
Capital invested by funds: $285M → $231M (-$54.8M)
22% less call options, than puts
Call options by funds: $5.2M | Put options by funds: $6.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$16.5M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$14.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$7.83M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$6.4M |
| 5 |
BlackRock
New York
|
+$5.84M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$26.4M |
| 2 |
AC
Armistice Capital
New York
|
-$19M |
| 3 |
RI
RTW Investments
New York
|
-$17.6M |
| 4 |
Renaissance Technologies
New York
|
-$13.5M |
| 5 |
Two Sigma Investments
New York
|
-$7.2M |
ALT Hedge Fund Activity: Q4 2020 in Review
88 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q4 2020, worth a combined $231M — down 19% from $285M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ALT positions and 21 closed out — a net gain of 16 holders — while 27 added to existing stakes and 16 trimmed.
The largest buyer was UBS Group, adding an estimated $16.5M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $26.4M sold.
- 88 institutional investors held Altimmune (ALT) as of Q4 2020, up from 72 in Q3 2020.
- Funds reported $231M of Altimmune stock for Q4 2020, down 19% quarter-over-quarter.
- 37 funds opened new Altimmune positions in Q4 2020 and 21 closed out, a net change of +16 holders.
- The largest Altimmune buyer in Q4 2020 was UBS Group, an estimated $16.5M added.
- The largest Altimmune seller in Q4 2020 was Avoro Capital Advisors, an estimated $26.4M sold.
Based on aggregated 13F filings for Q4 2020.